23
May
2022
Building a New Type of Drug Discovery Engine: Chris Gibson on The Long Run
Today’s guest on The Long Run is Chris Gibson. Chris the co-founder and CEO of Salt Lake City-based Recursion. The company was founded in 2013 when Chris was working in the lab of Dean Li at the University of Utah. The idea at Recursion is to do what it calls “industrialized drug discovery.” It combines some of the common tools... Read More
19
May
2022
A Path Forward for More Biotech Workers
Biotech needs more workers. More people who don’t have PhDs and MDs. The industry is 40 years old, and maturing. More companies are developing commercial products. Someone needs to make these products with precision, and at scale. Given the sophisticated nature of the products (cell therapy, gene therapy, advanced biologics, RNA medicines), the fragile global supply chains, and the importance... Read More
17
May
2022
Remix Gets $70m for Small Molecules to Alter RNA Processing
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
10
May
2022
MOMA Gets $150M to Make Small Molecules Against ATPases, Laborers of the Cell
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
9
May
2022
Fighting Cancer With Food and Drugs: Lew Cantley and Sid Mukherjee on The Long Run
Today’s guests on The Long Run are Lewis Cantley and Siddhartha Mukherjee. They are co-founders of San Francisco-based Faeth Therapeutics. Cantley, who recently moved to Dana Farber Cancer Institute, is a scientist well-known for his work on cancer metabolism. He discovered the PI3kinase pathway that’s an important regulator of normal cell growth, proliferation, metabolism – and which can become activated... Read More
5
May
2022
An Old Idea Whose Time Has Come
People are returning to the office. Many are rethinking the basics of work. So many people are exhausted and anxious. Biotech leaders are thinking carefully about how to proceed. An R&D-based industry needs people in environments that allow them to be energized, creative, collaborative. Here’s one simple idea: Walking meetings. The “walk and talk” business meeting isn’t new. But we... Read More
3
May
2022
Dianthus Gets $100m to Take Complement Inhibition to a New Level
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
28
Apr
2022
A Big Opportunity in Obesity
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
27
Apr
2022
The Timmerman Traverse for Life Science Cares Is Back, Fighting Poverty
The biotech community has plenty of people willing to work to support vulnerable members of our society. This year, I’m doing what I can to again mobilize the biotech community to fight poverty. I’m happy to announce the Timmerman Traverse for Life Science Cares. It’s a Presidential Traverse hike set for Sept. 11-14, 2022. This expedition builds on the success... Read More
21
Apr
2022
Regeneron Buys Checkmate, Bivalent Vaccine Progress, & a Fitting Acronym
Clinical trialists are always trying to come up with catchy study titles. I’m not a big fan of these acronyms, and try to avoid using them. They’re often forgettable. But this week I saw one that stood out as especially meaningful. Yale University researchers are running a new Long COVID study. It’s called – LISTEN. It stands for Listen to... Read More
19
Apr
2022
Microbiome-based Drug Development: Bernat Olle on The Long Run
Today’s guest on The Long Run is Bernat Olle. Bernat is the CEO of Cambridge, Mass.-based Vedanta Biosciences. The company was founded in 2010 by Puretech Health, in collaboration with a handful of academic founders. At the time, the faster/cheaper tools of DNA sequencing were making it possible for immunologists and microbiologists to gain a much more fine-grained view of... Read More
14
Apr
2022
GSK Acquires Sierra, Cimeio’s Shielded Cell Therapies, & AACR Highlights
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
13
Apr
2022
Versant-backed Cimeio Gets $50M for Shielded Stem Cell Therapies
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
23
Mar
2022
LifeMine Snags GSK Deal and $175m to Drive Fungus-Based Drug Discovery
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
14
Mar
2022
Structural Biology-Driven Drug Discovery: Ray Stevens on The Long Run
Today’s guest on the Long Run is Ray Stevens. Ray is the CEO of ShouTi. It’s a company that uses advanced structural biology technologies like cryo-EM images, and computational techniques, to discover small molecule drugs. The idea is to come up with orally available medicines that can build off the biological insights gained from protein or peptide drugs, but replace... Read More
10
Mar
2022
Aiming High, With a Team
Climbing Mt. Everest changed my life. The world’s highest mountain required digging deep — physically, mentally, emotionally. That was four years ago. That original climb was a success, raising $340,000 for cancer research at the Fred Hutchinson Cancer Research Center. But what came next meant more. The climb opened my mind to new ways of making a contribution, in addition... Read More
3
Mar
2022
Biotech Takes a Stand
Not long ago, biotech leaders steered clear of commenting on the issues of the day. Politics was limited to certain vested interests like drug pricing, science funding, and FDA regulation. Then came COVID-19 and the racial justice reckoning. Staring these terrible things in the face, people began to think more about their roles in the workplace, and in the community.... Read More
2
Mar
2022
Rondo Raises $67M to Make Bispecific T-cell Engagers for Solid Tumors
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
28
Feb
2022
Making Clinical Trials More Diverse: Michele Andrasik on The Long Run
Today’s guest on The Long Run is Michele Andrasik. I’m excited to have Michele on the show to talk about an undercovered aspect of the scientific enterprise. Michele is the director of social and behavioral science and community engagement for the HIV Vaccine Trials Network, and COVID-19 Prevention Network. She’s based in Seattle at the Fred Hutchinson Cancer Research Center,... Read More
17
Feb
2022
The Unsung Community Heroes Who Make Biotech Thrive
Every thriving biotech hub can trace its origins to one or two outstanding scientific institutions. But every thriving region can also trace some of its success back to community leaders. These are people who attend boring night meetings. They aren’t household names. They’re fine with that. These people were especially common in America after World War II. They laid down... Read More